大B细胞淋巴瘤CAR-T治疗后非复发死亡:DESCAR-T登记处LYSA研究
基于法国DESCAR-T登记处,分析2018年7月至2022年4月27家中心957例接受标准治疗阿基仑赛(n=598)或替沙仑赛(n=359)的大B细胞淋巴瘤患者,中位随访12.4个月,总体非复发死亡(NRM)48例(5.0%),早期9例(0.9%),晚期39例(4.1%),多因素分析显示糖尿病和清淋时铁蛋白升高与总体NRM风险增加相关。
要点
- 957例中总体NRM为5.0%(48例),早期NRM 0.9%(9例),晚期NRM 4.1%(39例)。
- 总体NRM原因中感染占56%(非COVID-19 29%、COVID-19 27%),细胞因子释放综合征10%。
- 多因素分析中糖尿病与清淋时铁蛋白升高均与总体NRM风险增加相关。
核心结论
- 大B细胞淋巴瘤患者CAR-T治疗后总体NRM为5.0%,以晚期NRM为主(占总体NRM的81%),感染是最主要死因。
研究设计与样本
- 利用法国DESCAR-T登记处的多中心数据,纳入2018年7月至2022年4月在27家法国中心接受标准治疗阿基仑赛(n=598)或替沙仑赛(n=359)的957例患者,分析NRM发生率、原因及危险因素。
主要发现
- 中位随访12.4个月,总体NRM 48例(5.0%),早期(输注后第28天前)9例(0.9%,占总体NRM 19%),晚期(输注后第28天及以后)39例(4.1%,占总体NRM 81%)。
- 总体NRM原因:感染56%(非COVID-19 29%、COVID-19 27%)、细胞因子释放综合征10%、卒中6%、脑出血6%、第二肿瘤6%、免疫效应细胞相关神经毒性4%、其他原因10%。
- 多因素分析中,糖尿病和清淋时铁蛋白水平升高均与总体NRM风险增加相关。
临床怎么用
- 作者认为结果可能有助于医生进行患者选择和管理,以减少CAR-T治疗后的NRM。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19 chimeric antigen receptor (CAR) T cells can induce prolonged remissions and potentially cure a significant proportion of patients with relapsed/refractory large B-cell lymphomas. However, some patients may die of causes unrelated to lymphoma after CAR T-cell therapy. To date, little is known about the nonrelapse mortality (NRM) after CAR T-cell therapy. Using the French DESCAR-T registry, we analyzed the incidence and causes of NRM and identified risk factors of NRM. We report on 957 patients who received standard-of-care axicabtagene ciloleucel (n = 598) or tisagenlecleucel (n = 359) between July 2018 and April 2022, in 27 French centers. With a median follow-up of 12.4 months, overall NRM occurred in 48 patients (5.0% of all patients): early (before day 28 after infusion) in 9 patients (0.9% of all patients and 19% of overall NRM), and late (on/after day 28 after infusion) in 39 patients (4.1% of all patients and 81% of overall NRM). Causes of overall NRM were distributed as follows: 56% infections (29% with non-COVID-19 and 27% with COVID-19), 10% cytokine release syndromes, 6% stroke, 6% cerebral hemorrhage, 6% second malignancies, 4% immune effector cell associated neurotoxicities, and 10% deaths from other causes. We report risk factors of early NRM and overall NRM. In multivariate analysis, both diabetes and elevated ferritin level at lymphodepletion were associated with an increased risk of overall NRM. Our results may help physicians in patient selection and management in order to reduce the NRM after CAR T-cell therapy.
引用
- Lemoine J, Bachy E, Cartron G, et al. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv. 2023. PMID: 37672383. doi:10.1182/bloodadvances.2023010624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。